Blockade of interleukin-23 signaling results in targeted protection of the colon and allows for separation of graft-versus-host and graft-versus-leukemia responses

• Published in: Blood 2010-06, Vol.115 (25), p.5249-5258
• Main Authors: Das, Rupali, Komorowski, Richard, Hessner, Martin J., Subramanian, Hariharan, Huettner, Claudia S., Cua, Daniel, Drobyski, William R.
• Format: Article
• Language: English
• Subjects: Acute Disease; Animals; Biological and medical sciences; Chronic Disease; Colon - immunology; Colon - pathology; Colonic Diseases - genetics; Colonic Diseases - immunology; Colonic Diseases - pathology; Colonic Diseases - prevention & control; Disease Models, Animal; Graft vs Host Disease - genetics; Graft vs Host Disease - immunology; Graft vs Host Disease - pathology; Graft vs Host Disease - prevention & control; Graft vs Leukemia Effect - genetics; Graft vs Leukemia Effect - immunology; Hematologic and hematopoietic diseases; Humans; Interleukin-23 Subunit p19; Leukemia - genetics; Leukemia - immunology; Leukemia - pathology; Leukemia - therapy; Medical sciences; Mice; Mice, Inbred BALB C; Mice, Knockout; Signal Transduction - genetics; Signal Transduction - immunology; Stem Cell Transplantation; Transplantation; Transplantation, Homologous
• ISSN: 0006-4971; 1528-0020; 1528-0020
• DOI: 10.1182/blood-2009-11-255422

Allogeneic stem cell transplantation is the most potent form of effective adoptive immunotherapy. The graft-versus-leukemia (GVL) effect mediated by the allogeneic graft, however, is typically coexpressed with graft-versus-host disease (GVHD), which is the major complication of allogeneic stem cell transplantation. In this study, we used genetic and antibody-based strategies to examine the effect that blockade of interleukin 23 (IL-23) signaling had on GVH and GVL reactivity in murine transplantation recipients. These studies demonstrate that the selective protection of the colon that occurs as a consequence of inhibition of IL-23 signaling reduces GVHD without loss of the GVL effect. The separation of GVH and GVL reactivity was noted in both acute and chronic hematologic malignancy models, indicating that this approach was not restricted by the kinetic profile of the underlying leukemia. Furthermore, a potent GVL response could be mounted in the colon under conditions where tumor cells migrated to this site, indicating that this organ did not serve as a sanctuary site for subsequent systemic relapse in GVHD-protected animals. These studies demonstrate that blockade of IL-23 signaling is an effective strategy for separating GVH and GVL responses and identify IL-23 as a therapeutic target for the regulation of alloresponses in humans.